Entries by IDEAL

IDeAl researchers discuss frontiers of confirmatory inference in small populations at MCP 2015

The IDeAl project is strongly represented to discuss multiplicity issues related to rare diseases at the 9th International Conference on Multiple Comparison Procedures MCP2015, September 2nd – 5th, in Hyderabad, India (http://www.mcp-conference.org/). This conference promotes research and applications of Multiple Comparison Procedures and provides a forum for interactions among industry practitioners, regulators,  research scientists from […]

IDeAl researchers disseminate latest findings at ISCB 2015

Several researchers of the IDeAl project are meeting up at ISCB 2015 in Utrecht in order to disseminate their latest findings on methodolgy for small population group trials. Ralf-Dieter Hilgers together with Armin Koch from the Asterix project gave a pre-conference workshop to their fellow researchers introducing them to Stratification and Randomisation in clinical trials. […]

Gerald Hlavin receives Arthur Linder Award

The International Biometrical Association honours Gerald Hlavin for his work “Evidence, Eminence and Extrapolation” with the renowned Arthur Linder Award. The research addresses the crucial question under which circumstances evidence from one subgroup can be transferred to another subgroup. This question arises especially in the context of clinical trials for children. The work is embedded […]

INI meeting in Cambridge was a big success

Several members of the IDeAl consortium got together at Isaac Newton Institute in Cambridge for one week (July 6th – 10th, 2015) to discuss mathematical implications for the design and analysis of experiments in healthcare. The meeting comprised two main parts: The first part was devoted to the fruitful exchange of the IDeAl consortium and […]

Austrian magazine “Profil” issues extensive article on Pediatrics

The Austrian magazine “Profil” released an extensive article on Paediatrics. Quoting Christoph Male (MUW), the article calls attention to the lack of drugs licensed for the tharapy of diseases in children. The smaller the child, the bigger are the differences of the effectiveness and safety of the drug. One reason for the lack of therapies […]